| Name | Title | Contact Details |
|---|
In todays environment, it has never been easier to feel left behind. Clearoute is a consulting agency with expertise in helping businesses to develop and implement customized solutions that are tailored to their specific needs and goals. You need a strategic ally who can harness brand, performance-marketing, tech & innovation, sales, and finance to deliver significant results and exponential growth. See the future. We transform your complex business challenges into simple profitable solutions.
ADB primarily provides specialized financial intermediation and related services with the objective of promoting a sustained and diversified agricultural and rural development as a foundation for the countrys over all development .In addition, to cultivate effective linkages between the agricultural sector and the rest of the economy and to complement the provision of banking services through out the country, ADB also provides ordinary commercial banking services , as well as servicing other sectors of the economy.
MGT is a national technology and advisory solutions leader serving state, local government, education (SLED) and targeted commercial clients. Our specialized solutions solve the most critical issues that live at the top of our clients leadership agenda. We partner to help clients build resilience, implement systematic change and strengthen their foundations, now and for the future. MGT is committed to impacting communities for good. For more information, visit us at mgt.us.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.